Cediranib

Cediranib is a medication used to treat various types of cancer, including renal cell carcinoma, glioblastoma, and other solid tumors. It is a tyrosine kinase inhibitor that works by blocking the activity of certain enzymes, known as tyrosine kinases, which are involved in the growth and survival of cancer cells. Cediranib is typically administered intravenously, usually every two weeks.

The drug was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of renal cell carcinoma that has spread to other parts of the body. It is also approved for the treatment of glioblastoma, a type of brain cancer, in combination with temozolomide. Cediranib is marketed under the brand name Cedira.

Common side effects of cediranib may include fatigue, nausea, vomiting, diarrhea, and high blood pressure. Serious side effects can include low blood cell counts, liver problems, and an increased risk of bleeding. It is important to discuss the potential risks and benefits of cediranib with a healthcare provider before starting treatment.

Cediranib is not typically used as a first-line treatment for cancer, but rather as a second or later-line therapy. Its effectiveness and safety profile may vary depending on the type of cancer and the individual patient's characteristics. Ongoing research is being conducted to further understand the optimal use of cediranib in different cancer types and to improve its efficacy and tolerability.